Global Patent Index - EP 1597284 A2

EP 1597284 A2 20051123 - PER (3,6-ANHYDRO) CYCLODEXTRINE DERIVATIVES, PRODUCTION AND USE THEREOF IN TRANSPORTING METAL ELEMENTS TO BIOLOGICAL TARGETS OR IN ORDER TO DECONTAMINATE BIOLOGICAL FLUIDS OR TARGETS

Title (en)

PER (3,6-ANHYDRO) CYCLODEXTRINE DERIVATIVES, PRODUCTION AND USE THEREOF IN TRANSPORTING METAL ELEMENTS TO BIOLOGICAL TARGETS OR IN ORDER TO DECONTAMINATE BIOLOGICAL FLUIDS OR TARGETS

Title (de)

DERIVATE VON PER-(3,6-ANHYDRO)-CYCLODEXTRINEN, IHRE HERSTELLUNG UND VERWENDUNG FÜR DAS TRANSPORTIEREN VON METALL-ELEMENTEN ZU BIOLOGISCHEN ZIELEN ODER ZUR DEKONTAMINIERUNG BIOLOGISCHER ZIELE ODER FLÜSSIGKEITEN

Title (fr)

DERIVES DE PER (3,6-ANHYDRO) CYCLODEXTRINES, LEUR PREPARATION ET LEUR UTILISATION POUR VEHICULER DES ELEMENTS METALLIQUES VERS DES CIBLES BIOLOGIQUES OU POUR DECONTAMINER DES CIBLES OU FLUIDES BIOLOGIQUES

Publication

EP 1597284 A2 20051123 (FR)

Application

EP 04708796 A 20040206

Priority

  • FR 2004050048 W 20040206
  • FR 0301474 A 20030207

Abstract (en)

[origin: FR2850972A1] Per(3,6-anhydro)cyclodextrin derivatives are new. Per(3,6-anhydro)cyclodextrin derivatives of formula (I) or (II) are new: [Image] R 1Q, OH, OR 3, OM, SH, SR 3, OCOR 3, NH 2, NHR 3, NR 3R 4, CONH 2, CONHR 3, CONR 3R 4, CN, COOR 3, OCH 2COOH, COOH, OSO 2R 3, N 3or R 3, at least one being Q; Q : a peptide, protein, lipid, oligonucleotide, polynucleotide, oligosaccharide, polysaccharide or biopolymer; R 3, R 4aliphatic or aromatic hydrocarbyl optionally substituted with halogen and optionally containing heteroatoms (O, S, N); M : alkali metal; R 2a bond or a spacer group; and n : 6-8. Independent claims are also included for: (1) preparing the per(3,6-anhydro)cyclodextrin derivatives; (2) metal complexes of the per(3,6-anhydro)cyclodextrin derivatives; (3) diagnostic and therapeutic compositions containing the complexes; (4) decontaminating a metal-contaminated biological medium in vitroby contacting the medium with a per(3,6-anhydro)cyclodextrin derivative as above. ACTIVITY : None given. MECHANISM OF ACTION : Radiotherapy. No biological data is given.

IPC 1-7

C08B 37/16; C02F 1/28; B01J 20/24; A61K 31/715

IPC 8 full level

A61P 39/00 (2006.01); B01J 20/26 (2006.01); B01J 45/00 (2006.01); C08B 37/00 (2006.01); C08B 37/16 (2006.01)

CPC (source: EP US)

A61P 39/00 (2017.12 - EP); B01J 20/26 (2013.01 - EP US); B01J 20/262 (2013.01 - EP US); B01J 20/265 (2013.01 - EP US); B01J 45/00 (2013.01 - EP US); C08B 37/0012 (2013.01 - EP US); C08B 37/0015 (2013.01 - EP US)

Citation (search report)

See references of WO 2004071639A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

FR 2850972 A1 20040813; FR 2850972 B1 20050311; EP 1597284 A2 20051123; JP 2006522840 A 20061005; US 2007148090 A1 20070628; WO 2004071639 A2 20040826; WO 2004071639 A3 20041007

DOCDB simple family (application)

FR 0301474 A 20030207; EP 04708796 A 20040206; FR 2004050048 W 20040206; JP 2006502174 A 20040206; US 54468004 A 20040206